Gastric neuroendocrine neoplasias: literature review

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Introduction: The gastric neuroendocrine neoplasias (NEN) are being diagnosed more and more often due to the wide spread of endoscopy methods and an increase in the imaging range, despite the rarity of the gastric neuroendocrine tumors (NETs) (which amounts to about 9% of all gastrointestinal neuroendocrine tumors and 0.3% of all gastric tumors). It is extremely important to distinguish in which case clinician and pathologist should suspect a neuroendocrine tumor and to classify it correctly, both at the stage of esophagogastroduodenoscopy and during pathological examination, because all these components affect the choice of the surgery extent, subsequent drug therapy, as well as the possibility of more accurate metastasis prognosis and the patient outcome.

Aim: The aim of this literature review is to systematize, generalize and discuss the recent data on gastric neuroendocrine tumors with a focus on current classifications including their critical analysis, and to show promising ways in the endoscopic and morphological diagnostics of these tumors, which, in turn, will have an effect on patient management. The search was performed among articles in the PubMed database (in English and German) and among Russian articles published on the eLibrary and Cyberleninka platforms using the following keywords: gastric neuroendocrine tumor, gastric carcinoid, gastric NET pathology, gastric NET morphology, gastric NET morphology, gastric NET diagnostics. The papers on surgical treatment methods, adjuvant therapy, as well as drug therapy with somatostatin analogues and other drugs were excluded. A brief retrospective journey into the history of neouroendocrine neoplasias serves to remind the histology and distribution of neuroendocrine cells in the gastric mucosa, followed by chronological review of NEN discovery and theory development up to the present moment. The morphological classification of gastric NET consisting of 4 possible types is highlighted: the correct interpretation of the pathological findings, taking into account not only the histological features of the tumor itself, but also of the adjacent mucosa, allows to suggest the appropriate managment, which fundamentally affects patient survival. The review provides other current classifications of the gastric neuroendocrine neoplasia depending on its location, embryogenesis, functional activity, histological grade (with a focus on the Ki-67 labeling index counting, and ways to improve the interobserver reliability in routine practice). Moreover, the differences in the gastric NET and NEC TNM classification are emphasized. The drawbacks of all classifications are discussed and the possibilities for their further development are considered. An important part of the review is the description of a possible immunohistochemical markers, since immunohistochemistry is widely used to confirm the diagnosis. In addition, INSM1 (insulinomaassociatedprotein 1), the new immunohistochemical and molecular marker for NEN is discussed: according to the literature, it contributes to more accurate assessment of the tumor malignant potential and the metastatic risk. Furthermore, modern methods of endoscopic and PET/CT imaging (68-gallium DOTATATE PET/CT, molecular imaging using SSTR (somatostatin receptor) PET/CT or GLP-1R (Glucagon-like peptide-1 receptor) SPECT (single photon emission computed tomography)/CT), which allows the clinician to suspect a NEN even before morphological analysis of the resected specimen and adequately select the extent of surgical intervention are shown.

Conclusion: We would like to reiterate the importance of further research on the gastric NET subtype pathogenesis and their clinical behavior, also of the correlation of the endoscopic, morphological, and immunohistochemical picture with the patient prognosis to improve managment tactics.


Full Text

Restricted Access

About the authors

Liudmila M. Mikhaleva

Research Institute of Human Morphology; City Clinical Hospital No. 31 of the Moscow City Health Department

Email: mikhalevalm@yandex.ru
SPIN-code: 2086-7513
Scopus Author ID: 6701472396

Russian Federation, 3, Tsuryupy street, Moscow, 117418; 42, Lobachevskogo street, Moscow, 119415

MD, PhD, Professor

Olesya A. Vasyukova

Research Institute of Human Morphology; City Clinical Hospital No. 31 of the Moscow City Health Department

Author for correspondence.
Email: o.vas.93@gmail.com
SPIN-code: 2242-0958
Scopus Author ID: 57195514112

Russian Federation, 3, Tsuryupy street, Moscow, 117418; 42, Lobachevskogo street, Moscow, 119415

Junior Researcher, Laboratory of Clincal Morphology, Research Institute of Human Morphology; pathologist in the 

Andrey E. Birukov

Research Institute of Human Morphology; City Clinical Hospital No. 31 of the Moscow City Health Department

Email: bervost@rambler.ru

Russian Federation, 3, Tsuryupy street, Moscow, 117418; 42, Lobachevskogo street, Moscow, 119415

MD, PhD

Konstantin Yu. Midiber

Research Institute of Human Morphology; City Clinical Hospital No. 31 of the Moscow City Health Department

Email: midiberkonst@gmail.com
ORCID iD: 0000-0002-1426-968X
SPIN-code: 6891-6636

Russian Federation, 3, Tsuryupy street, Moscow, 117418; 42, Lobachevskogo street, Moscow, 119415

Emma P. Akopyan

Research Institute of Human Morphology

Email: vanilsheep@yandex.ru
ORCID iD: 0000-0002-1826-9169

Russian Federation, 3, Tsuryupy street, Moscow, 117418

Tatyana N. Khovanskaya

Research Institute of Human Morphology; City Clinical Hospital No. 31 of the Moscow City Health Department

Email: zimavnebe@mail.ru
ORCID iD: 0000-0002-5646-2605
SPIN-code: 3157-3880

Russian Federation, 3, Tsuryupy street, Moscow, 117418; 42, Lobachevskogo street, Moscow, 119415

Mikhail Yu. Guschin

Research Institute of Human Morphology

Email: guschin.michail@yandex.ru
ORCID iD: 0000-0002-1041-8561
SPIN-code: 8401-8694

Russian Federation, 3, Tsuryupy street, Moscow, 117418

MD, PhD

References

  1. Solcia E, Capella C, Vassallo G, Buffa R. Endocrine cells of the gastric mucosa. Int Rev Cytol. 1975;42:223–286. doi: 10.1016/s0074-7696(08)60982-1.
  2. Кит О.И., Дерижанова И.С., Карнаухов Н.С. Вопросы классификации нейроэндокринных опухолей желудка // Вопросы онкологии. ― 2016. ― Т.62. ― №5. ― С. 573−579. [Kit OI, Derizhanova IS, Karnaukhov NS. Issues on classification of gastric neuroendocrine tumors. Problems in oncology. 2016;62(5):573−579. (In Russ).]
  3. Oberndorfer S. Karzinoide tumoren des dünndarms. Frankf Z Pathol. 1907;1:425–432. (In German).
  4. Klöppel G. Oberndorfer and his successors: from carcinoid to neuroendocrine carcinoma. Endocr Pathol. 2007;18(3):141–144. doi: 10.1007/s12022-007-0021-9.
  5. Rindi G, Luinetti O, Cornaggia M, et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology. 1993;104(4):994−1006. doi: 10.1016/0016-5085(93)90266-f.
  6. Capella C, Heitz PU, Höfler H, et al. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch. 1995;425(6):547–560. doi: 10.1007/bf00199342.
  7. Moreira RK, Washington K. Pathology of gastrointestinal neuroendocrine tumors: an update. Surg Pathol Clin. 2010;3(2):327–347. doi: 10.1016/j.path.2010.05.003.
  8. Cockburn AN, Morgan CJ, Genta RM. Neuroendocrine proliferations of the stomach: a pragmatic approach for the perplexed pathologist. Adv Anat Pathol. 2013;20(3):148−157. doi: 10.1097/PAP.0b013e31828d185d.
  9. Shi C, Adsay V, Bergsland EK, et al. CAP protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the stomach. Includes pTNM requirements from the 8th Edition, AJCC Staging Manual; 2017. Avalaible from: https://documents.cap.org/protocols/cp-stomach-net-17protocol-4001.pdf.
  10. Daskalakis K, Tsoli M, Karapanagioti A, et al. Recurrence and metastatic potential in type 1 gastric neuroendocrine neoplasms. Clin Endocrinol (Oxf). 2019;91(4):534−543. doi: 10.1111/cen.14055.
  11. Abraham SC, Aidan Carney J, Ooi A, et al. Achlorhydria, parietal cell hyperplasia, and multiple gastric carcinoids: a new disorder. Am J Surg Pathol. 2005;29(7):969–975. doi: 10.1097/01.pas.0000163363.86099.9f.
  12. Ooi A, Ota M, Katsuda S, et al. An unusual case of multiple gastric carcinoids associated with diffuse endocrine cell hyperplasia and parietal cell hypertrophy. Endocr Pathol. 1995;6(3):229–237. doi: 10.1007/bf02739887.
  13. Waldum HL, Hauso Ø, Brenna E, et al. Does long-term profound inhibition of gastric acid secretion increase the risk of ECL cell-derived tumors in man? Scand J Gastroenterol. 2016;51(7):767–773. doi: 10.3109/00365521.2016.1143527.
  14. La Rosa S, Sessa F, Uccella S. Mixed neuroendocrine-nonneuroendocrine neoplasms (MiNENs): unifying the concept of a heterogeneous group of neoplasms. Endocr Pathol. 2016;27(4):284–311. doi: 10.1007/s12022-016-9432-9.
  15. Delle Fave G, O’Toole D, Sundin A, et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):119–124. doi: 10.1159/000443168.
  16. Gluckman CR, Metz DC. Gastric neuroendocrine tumors (carcinoids). Cur Gastroenterol Rep. 2019;21(4):13. doi: 10.1007/s11894-019-0684-7.
  17. Gastric neuroendocrine neoplasms. In: WHO Classification of tumours. Digestive system tumours. 5th ed. Lyon: IARC; 2019. Рр. 104−109.
  18. Kim BS, Park YS, Yook JH, Kim BS. Comparison of relapse-free survival in gastric neuroendocrine carcinoma (WHO grade 3) and gastric carcinoma. Therap Adv Gastroenterol. 2017;10(5):407−415. doi: 10.1177/1756283X17697870.
  19. Клинические рекомендации «Нейроэндокринные опухоли». ― М., 2017. [Klinicheskie rekomendatsii “Neiroendokrinnye opukholi”. Moscow; 2017. (In Russ).] Доступно по: https://oncology-association.ru/files/clinical-guidelines_adults/neiroendokrinnye_opukholi.pdf. Ссылка активна на 12.11.2019.
  20. Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103(2):186−194. doi: 10.1159/000443172.
  21. Делекторская В.В., Кушлинский Н.Е. Нейроэндокринные опухоли пищеварительной системы: морфологический спектр и клеточная пролиферация (индекс Ki-67) // Вестник РАМН. ― 2013. ― Т.68. ― №5. ― С. 28–37. [Delektorskaya VV, Kushliskiy NE. Neuroendocrine tumors of digestive system: morphologic spectrum and cell proliferation (КІ67 index). Annals of the Russian Academy of Medical Sciences. 2013;68(5):28–37. (In Russ).] doi: 10.15690/vramn.v68i5.660.
  22. Grillo F, Albertelli M, Brisigotti MP, et al. Grade increases in gastro-enteropancreatic neuroendocrine tumor metastases compared to the primary tumor. Neuroendocrinology. 2016;103(5):452−459. doi: 10.1159/000439434.
  23. Solcia E, Arnold R, Capella C, et al. Tumours of the stomach: neuroendocrine neoplasms of the stomach. In: Bosman FT, Carneiro F, Hruban RH, et al., eds. WHO Classification of tumours of the digestive system. 2nd ed. Lyon: IARC; 2010. Рр. 64–68.
  24. Tang LH, Untch BR, Reidy DL, et al. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin Cancer Res. 2016;22(4):1011–1017. doi: 10.1158/1078-0432.CCR-15-0548.
  25. Milione M, Maisonneuve P, Spada F, et al. The clinicopathologic heterogeneity of Grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories. Neuroendocrinology. 2017;104(1):85−93. doi: 10.1159/000445165.
  26. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO Classification of tumours of the digestive system. Histopathology. 2020;76(2):182−188. doi: 10.1111/his.13975.
  27. Amin MB, Edge SB, Greene FL, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “Personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93−99. doi: 10.3322/caac.21388.
  28. Fazio N, Milione M. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: new insights and treatment implications. Cancer Treat Rev. 2016;50:61−67. doi: 10.1016/j.ctrv.2016.08.006.
  29. Milione M, Fazio N. G3 GEP NENs category: are basic and clinical investigations well integrated? Endocrine. 2018;60(1):28−30. doi: 10.1007/s12020-017-1365-7.
  30. Rosenbaum JN, Guo Z, Baus RM, et al. INSM1 a novel immunohistochemical and molecular marker for neuroendocrine and neuroepithelial neoplasms. Am J Clin Pathol. 2015;144(4):579−591. doi: 10.1309/AJCPGZWXXBSNL4VD.
  31. Tsukamoto H, Mizoshita T, Sasaki M, et al. Long-term high-dose proton pump inhibitor administration to Helicobacter pylori-infected Mongolian gerbils enhances neuroendocrine tumor development in the glandular stomach. Asian Pac J Cancer Prev. 2011;12(4):1049–1054.
  32. Cao L, Mizoshita T, Tsukamoto T, et al. Development of carcinoid tumors of the glandular stomach and effects of eradication in Helicobacter pylori-infected Mongolian gerbils. Asian Pac J Cancer Prev. 2008;9(1):25–30.
  33. Deppen SA, Liu E, Blume JD, et al. Safety and efficacy of 68Ga-Dotatate PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors. J Nucl Med. 2016;57(5):708−714. doi: 10.2967/jnumed.115.163865.
  34. Cavallaro A, Zanghì A, Cavallaro M, et al. The role of 68-Ga-Dotatoc CT-PET in surgical tactic for gastric neuroendocrine tumors treatment: our experience: a case report. Int J Surg. 2014;12(Suppl 1):225–231. doi: 10.1016/j.ijsu.2014.05.017.
  35. Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2018;68(6):471−487. doi: 10.3322/caac.21493.
  36. Schraml C, Schwenzer NF, Sperling O, et al. Staging of neuroendocrine tumours: comparison of [(6)(8)Ga]Dotatoc multiphase PET/CT and whole-body MRI. Cancer Imaging. 2013;13(1):63−72. doi: 10.1102/1470-7330.2013.0007.
  37. Reubi JC, Waser B. Triple-peptide receptor targeting in vitro allows detection of all tested gut and bronchial NETs. J Nucl Med. 2015;56(4):613−615. doi: 10.2967/jnumed.114.153189.
  38. Baumann T, Rottenburger C, Nicolas G, Wild D. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) ― imaging and staging. Best Pract Res Clin Endocrinol Metab. 2016;30(1):45−57. doi: 10.1016/j.beem.2016.01.003.
  39. Патент РФ на изобретение RU № 2613300. Кит О.И., Дерижанова И.С., Карнаухов Н.С. Cпособ диагностики низкодифференцированного нейроэндокринного рака желудка. [Patent RUS № 2613300. Kit OI, Derizhanova IS, Karnaukhov NS. Sposob diagnostiki nizkodifferentsirovannogo neiroendokrinnogo raka zheludka. (In Russ).] Доступно по: https://yandex.ru/patents/doc/RU2613300C1_20170315. Ссылка активна на 12.11.2019.
  40. Kloeppel G. [Neuroendocrine neoplasms: two families with distinct features unified in one classification. (In German)]. Pathologe. 2019;40(3):211–219. doi: 10.1007/s00292-019-0594-3.

Supplementary files

There are no supplementary files to display.

Statistics

Views

Abstract - 324

PDF (Russian) - 1

Cited-By


PlumX

Dimensions



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies